Diabetic Nephropathy Market Forecast 2036: Rising Demand, Novel Therapies, and Commercial Potential - DelveInsight

The Diabetic Nephropathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Nephropathy pipeline products will significantly revolutionize the Diabetic Nephropathy market dynamics.

DelveInsight's "Diabetic Nephropathy Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Diabetic Nephropathy, historical and forecasted epidemiology as well as the Diabetic Nephropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Diabetic Nephropathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Get a Free sample for the Diabetic Nephropathy Market Report:
https://www.delveinsight.com/report-store/diabetic-nephropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Diabetic Nephropathy Market Report:
• The Diabetic Nephropathy market size was valued ~USD 2,800 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2022-2036)
• In March 2026, Kodiak Sciences reported positive topline findings from the Phase III GLOW2 superiority trial evaluating ZENKUDA in patients with diabetic retinopathy. ZENKUDA is an intravitreal anti-VEGF biologic developed using Kodiak's proprietary antibody biopolymer conjugate (ABC) platform, designed to provide sustained therapeutic activity within the eye.
• According to REGENXBIO's Q4 2025 financial and operational update, the company, in partnership with AbbVie, expects to release topline results from the pivotal ATMOSPHERE and ASCENT trials evaluating sura-vec delivered via the subretinal route in Q4 2026. Pending successful outcomes, global regulatory filings are planned for 2027.
• According to CDC data, the prevalence of diabetic retinopathy in the US rises with age, affecting 13% of individuals under 25 and increasing to 28.4% among those aged 65-79.
• Based on secondary analysis, among adults aged 40 and above, approximately 8.94 million are affected by diabetic retinopathy, with 1.71 million experiencing vision-threatening complications. These statistics highlight the urgent need for age-specific screening programs and early intervention strategies.
• Diabetic retinopathy affects approximately 3%-4.1% of the European population, underscoring its significant impact on public health. Prevalence of diabetic retinopathy in those over age 60 is highest in France, followed by Germany. This prevalence highlights the growing burden of diabetes-related complications in the region, emphasizing the need for widespread screening, early detection, and proactive management to mitigate vision loss among affected individuals.
• According to secondary analysis, at any given point, 15-30% of the diabetic population suffers from some form of diabetic retinopathy. Approximately half of the patients are unaware of their condition due to a lack of symptoms and mild non-proliferative disease that might go undetected. Although diabetic retinopathy, through diabetic macular edema and proliferative diabetic retinopathy, is the leading cause of vision loss among working-age populations in the US and many other countries, much of the causative ophthalmic pathology is treatable.
• According to the American Association of Ophthalmology, non-proliferative diabetic retinopathy is notably prevalent across Europe, with the UK exhibiting the highest rate at 48%, followed by Spain at 38.9%, while Germany reports a significantly lower prevalence of 10%. These variations highlight regional disparities, emphasizing the need for tailored preventive strategies and healthcare interventions to address diabetic eye complications effectively.
• Based on secondary research, diabetic retinopathy affects around 3 million individuals in Japan, ranking as the third leading cause of visual impairment. This substantial prevalence underscores the growing impact of diabetes-related eye diseases, highlighting the need for improved screening, early intervention, and comprehensive management strategies to reduce vision loss among affected populations.
• Key Diabetic Nephropathy Companies: Praetego, Mitsubishi Tanabe Pharma, Regenacy Pharmaceuticals, WinSanTor, Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, Vertex Pharmaceuticals Incorporated, Eli Lilly and Company, and others
• Key Diabetic Nephropathy Therapies: PTG-630, MT-8554, Ricolinostat, WST 057, Engensis, VM202, LX9211, GRC 17536, Ricolinostat, VX-548, LY3857210, and others
• The Diabetic Nephropathy epidemiology based on gender analyzed that the prevalence of Diabetic Nephropathy increases significantly with age

Diabetic Nephropathy Overview
Diabetic nephropathy is a serious kidney-related complication of diabetes, characterized by damage to the blood vessels in the kidneys due to prolonged high blood sugar levels. This condition leads to a gradual decline in kidney function and can result in end-stage renal disease (ESRD) if not managed properly. Early signs of diabetic nephropathy include the presence of protein in the urine (albuminuria) and elevated blood pressure. Risk factors for developing this condition include poor glycemic control, hypertension, and a family history of kidney disease. Management focuses on controlling blood sugar and blood pressure levels, as well as lifestyle changes and medications to slow the progression of kidney damage.

To Know in detail about the Diabetic Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Nephropathy Market Insights
https://www.delveinsight.com/sample-request/diabetic-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Diabetic Nephropathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diabetic Nephropathy Epidemiology Segmentation:
The Diabetic Nephropathy market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalent Cases of Diabetic Retinopathy
• Gender-specific Prevalent Cases of Diabetic Retinopathy
• Type-specific Prevalent Cases of Diabetic Retinopathy
• Age-specific Prevalent Cases of Diabetic Retinopathy
• Total-treated Cases of Diabetic Retinopathy

Download the report to understand which factors are driving Diabetic Nephropathy epidemiology trends @ Diabetic Nephropathy Epidemiological Insights
https://www.delveinsight.com/sample-request/diabetic-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Diabetic Nephropathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Nephropathy market or expected to get launched during the study period. The analysis covers Diabetic Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Diabetic Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Nephropathy Therapies and Key Companies
• Ranibizumab (LUCENTIS): Genentech
• Aflibercept (EYLEA): Ionis Pharmaceuticals and AstraZeneca
• Tarcocimab tedromer (KSI-301): Kodiak Sciences
• ABBV-RGX-314: Regenxbio/AbbVie
• PTG-630: Praetego
• MT-8554: Mitsubishi Tanabe Pharma
• Ricolinostat: Regenacy Pharmaceuticals
• WST 057: WinSanTor
• Engensis: Helixmith
• VM202: Helixmith
• LX9211: Lexicon Pharmaceuticals
• GRC 17536: Glenmark Pharmaceuticals
• Ricolinostat: Regenacy Pharmaceuticals
• VX-548: Vertex Pharmaceuticals Incorporated
• LY3857210: Eli Lilly and Company

To know more about Diabetic Nephropathy treatment, visit @ Diabetic Nephropathy Medications
https://www.delveinsight.com/sample-request/diabetic-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Diabetic Nephropathy Market Drivers
• Rising Diabetes Prevalence: The growing global burden of type 1 and type 2 diabetes is increasing the number of patients at risk of developing diabetic nephropathy.
• Increasing Awareness and Early Diagnosis: Improved screening programs and greater awareness of diabetic kidney disease are leading to earlier detection and treatment.
• Advancements in Therapeutics: The introduction of novel therapies, including SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and emerging pipeline candidates, is driving market growth.
• Growing Healthcare Expenditure: Increased investments in chronic disease management and kidney care are supporting market expansion.

Diabetic Nephropathy Market Barriers
• High Treatment Costs: Advanced therapies and long-term disease management can impose a significant financial burden on patients and healthcare systems.
• Limited Disease Reversibility: Current treatments primarily slow disease progression rather than cure the condition, limiting therapeutic outcomes.
• Underdiagnosis in Early Stages: Many patients remain undiagnosed until the disease has significantly progressed, affecting treatment effectiveness.
• Adverse Effects and Safety Concerns: Some therapies may be associated with side effects that impact patient adherence and treatment adoption.

Scope of the Diabetic Nephropathy Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Diabetic Nephropathy Companies: Praetego, Mitsubishi Tanabe Pharma, Regenacy Pharmaceuticals, WinSanTor, Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, Vertex Pharmaceuticals Incorporated, Eli Lilly and Company, and others
• Key Diabetic Nephropathy Therapies: PTG-630, MT-8554, Ricolinostat, WST 057, Engensis, VM202, LX9211, GRC 17536, Ricolinostat, VX-548, LY3857210, and others
• Diabetic Nephropathy Therapeutic Assessment: Diabetic Nephropathy current marketed and Diabetic Nephropathy emerging therapies
• Diabetic Nephropathy Market Dynamics: Diabetic Nephropathy market drivers and Diabetic Nephropathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Diabetic Nephropathy Unmet Needs, KOL's views, Analyst's views, Diabetic Nephropathy Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.